Tuesday, April 10, 2012

Metformin may improve survival in Pancreatic cancer patients

In a retrospective study involving 302 patients, conducted by Donghui Li, Ph.D., a professor at The University of Texas MD Anderson Cancer Center, it was found that in patients who have both diabetes and pancreatic cancer, the use of metformin significantly improves survival rates. These benefits were seen in all stages of pancreatic cancer, except in patients where metastasis has happened.


In the study, at 1 and 2 year respectively, the use of metformin was assocated with a survival rate of  63.9 percent and 30.1 percent as compared to 46.3 and 15.4 percent for those do were not given metformin.
The median OS was 15.2 months for those who took metformin and 11.1 months for those who didn't take the drug.
Study has been  published in Clinical Cancer Research, a journal of the American Association for Cancer Research.